Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis

• Status: Completed
• Trial end date: 2016-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Intra-peritoneal administration of antibiotics covering both gram-positive and gram-negative organisms was recommended as first-line regimen for the management of peritoneal dialysis related peritonitis. Oral administration of quinolones can also achieve effective serum concentrations, and is more convenient and economical. We conducted a pilot randomized controlled study to compare the effects on peritonitis cure and relapsing rates between oral moxifloxacin plus IP vancomycin and conventional IP vancomycin plus ceftazidime.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital
• Treatments: Ceftazidime; Fluoroquinolones; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination; Vancomycin

Criteria

Inclusion Criteria:

• incident or prevalent peritoneal dialysis patients

• diagnosis of acute peritonitis according to ISPD guideline

• age >18 years

Exclusion Criteria:

• receiving antibiotic treatment for other reasons when peritonitis occurred

• contraindication to cephalosporin, vancomycin, or fluoroquinolones

• concomitant exit-site or tunnel infection

• requirement for immediate transfer to hemodialysis due to sepsis, gastrointestinal perforation or visceral inflammation, severe bowel obstruction, or ultrafiltration failure at the initiation of peritonitis

• inability to tolerate oral administration due to severe gastrointestinal complication or other reasons

• history of psychological illness or condition which interfered with ability to understand or comply with the requirements of the study

• pregnant or breast-feeding